<DOC>
	<DOCNO>NCT00095459</DOCNO>
	<brief_summary>Background : - BAY 43-9006 inhibitor wild-type mutant B-Raf c-Raf kinase isoforms vitro , also inhibit p38 , c-kit , VEGFR-2 PDGFR-Beta affect tumor growth well possibly promote apoptosis event downstream c-Raf . - Bevacizumab humanize IgG1 monoclonal antibody ( MAb ) bind biologically active isoforms human vascular endothelial growth factor ( VEGF , VEGF-A ) high affinity ( k ( ) = 1.1nM ) - The common adverse event associate bevacizumab severity include asthenia , pain , headache , hypertension , diarrhea , stomatitis , constipation , epistaxis , dyspnea , dermatitis proteinuria . - This Phase I trial open patient solid tumor . Objectives : - Determine safety toxicity combination BAY 43-9006 ( Sorafenib ) bevacizumab . - Determine estimate biochemical change Ras-Raf-MAPK VEGF signal transduction pathway tumor stromal cell response treatment MTD , least pilot fashion , change statistically significant . Eligibility : - Adults histologically document solid tumor malignancy metastatic unresectable standard curative therapy exist longer effective . - Patients must prior chemotherapy , radiation therapy , hormonal therapy , biological therapy least 4 week . - All patient enrol cohort 2 must least one lesion amenable biopsy . - ECOG performance status 0 1 adequate organ marrow function . Design : - Cohort I receive BAY 43-9006 bevacizumab together start study dose escalation fashion . - Cohort II randomize agent receive cycle one . Cycles 2 beyond treat use agent . - Tumor biopsy obtain patient Cohort II treatment , two week mono-therapy , two week combinatorial therapy . - DCE-MRI study obtain patient Cohort II treatment , two week monotherapy , four week monotherapy , two week combinatorial therapy . - FDG-PET study obtain patient Cohort II treatment , two week mono-therapy , two week combinatorial therapy . - Patients evaluated toxicity clinic every 2 week Cycles 1 2 , every 4 week . - Patients evaluate response every 8 week use RECIST criterion . - Approximately 62 patient need achieve objective trial .</brief_summary>
	<brief_title>BAY 43-9006 ( Sorafenib ) Bevacizumab ( Avastin ) To Treat Solid Tumors</brief_title>
	<detailed_description>Background : - BAY 43-9006 inhibitor wild-type mutant B-Raf c-Raf kinase isoforms vitro , also inhibit p38 , c-kit , VEGFR-2 PDGFR-Beta affect tumor growth well possibly promote apoptosis event downstream c-Raf . - Bevacizumab humanize IgG1 monoclonal antibody ( MAb ) bind biologically active isoforms human vascular endothelial growth factor ( VEGF , VEGF-A ) high affinity ( k ( ) = 1.1nM ) - The common adverse event associate bevacizumab severity include asthenia , pain , headache , hypertension , diarrhea , stomatitis , constipation , epistaxis , dyspnea , dermatitis proteinuria . - This Phase I trial open patient solid tumor . Objectives : - Determine safety toxicity combination BAY 43-9006 ( Sorafenib ) bevacizumab . - Determine estimate biochemical change Ras-Raf-MAPK VEGF signal transduction pathway tumor stromal cell response treatment MTD , least pilot fashion , change statistically significant . Eligibility : - Adults histologically document solid tumor malignancy metastatic unresectable standard curative therapy exist longer effective . - Patients must prior chemotherapy , radiation therapy , hormonal therapy , biological therapy least 4 week . - All patient enrol cohort 2 must least one lesion amenable biopsy . - ECOG performance status 0 1 adequate organ marrow function . Design : - Cohort I receive BAY 43-9006 bevacizumab together start study dose escalation fashion . - Cohort II randomize agent receive cycle one . Cycles 2 beyond treat use agent . - Tumor biopsy obtain patient Cohort II treatment , two week mono-therapy , two week combinatorial therapy . - DCE-MRI study obtain patient Cohort II treatment , two week monotherapy , four week monotherapy , two week combinatorial therapy . - FDG-PET study obtain patient Cohort II treatment , two week mono-therapy , two week combinatorial therapy . - Patients evaluated toxicity clinic every 2 week Cycles 1 2 , every 4 week . - Patients evaluate response every 8 week use RECIST criterion . - Approximately 62 patient need achieve objective trial .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must solid tumor malignancy metastatic unresectable standard curative therapy exist longer effective . Patients must histological documentation cancer confirm Laboratory Pathology/NCI . Patients must prior chemotherapy , radiation therapy , hormonal therapy , biological therapy least 4 week . Patients receive mitomycin C , nitrosoureas , carboplatin must 6 week last administration chemotherapy . Patients prostate cancer must continue receive LHRH agonist ( unless orchiectomy perform ) . Patients receive complementary/alternative therapy study . Furthermore , complementary therapy stop least 7 day prior enrollment . Any patient undergone therapy monoclonal antibody must least 8 week last treatment . All patient enrol cohort 2 must least one lesion amenable biopsy . This determination make member interventional radiology team surgical associate investigator associate investigator . This requirement necessary patient cohort 1 . Age great 18 year . ECOG performance status 0 1 . Life expectancy great 3 month . Patients must adequate organ marrow function define : Leukocytes great 3,000/microliter Absolute neutrophil count great 1,200/microliter Platelets great 100,000/microliter Total Bilirubin less equal 1.5 time institutional upper limit normal AST ( SGOT ) ALT ( SGPT ) less equal 2.5 time institutional upper limit normal Creatinine le equal 1.5 mg/dL OR creatinine clearance great 45 mL/min/1.73 ( 2 ) patient creatinine level institutional normal . Activated partial thromboplastin time ( PTT ) less 1.25 time institutional upper limit normal Prothrombin Time ( PT ) OR INR le 1.25 time institutional upper limit normal Amylase Lipase less equal institutional upper limit normal Spot Urine Protein Creatinine Ratio le 0.5 ; If result 0.5 , 24hour urine protein excretion must less 1000mg Patients must recover toxicity relate prior therapy least CTEP grade 1 ( define CTC 3.0 ) . Chronic stable grade 2 peripheral neuropathy secondary neurotoxicity prior therapy may consider case case basis Principal Investigator . Women childbearing potential men must agree use adequate contraception ( abstinence ; hormonal barrier method birth control ) study least 2 month completion . Pregnant woman eligible study . Ability understand willingness sign write informed consent document . EXCLUSION CRITERIA : Brain metastasis Patients history remote CNS metastases undergone `` curative therapy '' radiation therapy , gamma knife therapy , surgery remain without recurrence period great equal 2 year consider casebycase basis . CNS image mandate patient . However , clinical suspicion CNS involvement , contrast CT MRI brain require . Screening CNS scan require certain tumor type relatively high risk CNS metastasis , include limited melanoma , RCC , breast , lung . Thrombotic embolic event within past 6 month cerebrovascular accident ( include transient ischemic attack ) , pulmonary embolism , unstable angina , myocardial infarction . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( AHA Class II worse ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients evidence active infection become eligible reconsideration 7 day complete antibiotic therapy . HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction BAY 439006 , bevacizumab , and/or combination . Patients treat BAY 439006 bevacizumab exclude Hypertension define systolic blood pressure great 140 mmHg diastolic pressure great 90 mmHg despite optimal medical management . Proteinuria define 24hour urine protein excretion great 1000 mg. Spot urine analysis protein creatinine ratio ( UPC ) 0.5 great require 24hour urine determine eligibility enrollment . Therapeutic anticoagulation coumadin , heparin , heparinoids . Serious nonhealing wound ( include wound heal secondary intention ) , acute nonhealing ulcer , bone fracture within 3 month fracture . History abdominal fistula , gastrointestinal perforation intraabdominal abcesses within 28 day exclude . Evidence bleed diathesis Impairment swallow would preclude administration BAY 439006 . History hemoptysis surgery within past 28 day . Patients squamous cell carcinoma lung exclude due risk fatal pulmonary hemorrhage . If patient history type primary lung cancer hemoptysis , exclude . History high grade varix . Use herbal supplement permit within 14 day trial commencement study . Vitamin supplement ( typical single multivitamin ) usage discourage unless clearly indicate exist medical condition . An Associate Principal Investigator discretion regard vitamin supplement permit . Patients know hypersensitivity Chinese hamster ovary cell product recombinant human antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 23, 2014</verification_date>
	<keyword>Raf-Kinase Inhibitor</keyword>
	<keyword>Combinatorial Therapy</keyword>
	<keyword>Pathway Profiling</keyword>
	<keyword>VEGFR</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>VEGF</keyword>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Metastatic Uresectable Solid Tumors</keyword>
</DOC>